Higher ORR (59%) in patients with EGFR T790M mutation-positive NSCLC vs. patients with T790M-negative disease (TIGER-X). Pooled TIGER-X/TIGER-2 data revealed lower rate of confirmed response (28–34%) [67]. Mature confirmed response rate (TIGER-X) 45% [68]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.